Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating Dynavax for potential breaches of fiduciary duty and other legal violations related to its transaction with Sanofi, which involves a cash offer for shareholders [1][3]. Group 1: Transaction Details - Dynavax shareholders will receive $15.50 per share, valuing the company at approximately $2.2 billion [2]. - The transaction includes substantial benefits for Dynavax insiders as part of change of control arrangements [2]. Group 2: Investigation Focus - The transaction agreement imposes significant penalties on Dynavax for accepting competing bids, which may limit shareholder options [3]. - The investigation will assess whether the Dynavax board of directors is fulfilling their fiduciary duties to all shareholders [3].